Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRB1ADRB2ADRB3CYP11B1DPP4FGFR1FGFR2FGFR3FGFR4HRH1JAK1JAK2JAK3KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITNAOPRD1OPRK1OPRM1PPDGFRBPIK3CDSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASMOTYK2polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL8037789 | 1.00 | CA4 (0.37) | CA4CA2SLC34A1FDPSALDH1A1 | |
| Phosphoric Acid SCHEMBL27437 | 1.00 | — | — | |
| Phosphoric Acid SCHEMBL122711 | 1.00 | CA4 (0.37) | CA4CA2SLC34A1FDPSALDH1A1 | |
| Phosphoric Acid SCHEMBL1317793 | 1.00 | CA4 (0.37) | CA4CA2SLC34A1FDPSALDH1A1 | |
| Phosphoric Acid SCHEMBL301627 | 1.00 | CA4 (0.37) | CA4CA2SLC34A1FDPSALDH1A1 | |
| Phosphoric Acid SCHEMBL1803051 | 0.96 | CA4 (0.35) | CA4CA2SLC34A1FDPSALDH1A1 | |
| Phosphoric Acid SCHEMBL5594607 | 0.96 | CA4 (0.35) | CA4CA2SLC34A1FDPSALDH1A1 | |
| Phosphoric Acid SCHEMBL28765734 | 0.96 | CA4 (0.35) | CA4CA2SLC34A1FDPSALDH1A1 | |
| Phosphoric Acid SCHEMBL21827143 | 0.96 | — | — | |
| Phosphoric Acid SCHEMBL5594606 | 0.96 | CA4 (0.35) | CA4CA2SLC34A1FDPSALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2338923-B1 | Polyurethane with a biocidal polyuric material as comonomer | OBERWALDER SEBASTIAN (DE) | 2017-10-18 | — | — | EP | claimed |
| EP-2338342-A1 | Polyuric material with biocidal characteristics | Oberwalder, Sebastian (DE) | 2011-06-29 | — | — | EP | claimed |
| EP-2338923-A1 | Polyurethane with a biocidal polyuric material as comonomer | Oberwalder, Sebastian (DE) | 2011-06-29 | — | — | EP | claimed |
| US-12505900-B2 | Integrated synthesis and analysis systems and methods of use thereof | PURDUE RESEARCH FOUNDATION (US) | 2025-12-23 | — | — | US | disclosed |
| US-12391929-B2 | Polymerase-nucleotide conjugates for sequencing by trapping | ELEMENT BIOSCIENCES, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| WO-2025074271-A1 | MYT1 INHIBITORS FOR THE TREATMENT OF CANCERS HARBORING REPLICATION STRESS MUTATIONS | REPARE THERAPEUTICS INC. (CA) | 2025-04-10 | — | — | WO | disclosed |
| US-20240168030-A1 | DIRECT FLUORESCENT GLYCAN LABELING | BIO TECHNE CORP (US) | 2024-05-23 | — | — | US | disclosed |
| CN-117545483-A | Compounds and methods for treating chemotherapy-related gastrointestinal side effects | 上海岸阔医药科技有限公司 | 2024-02-09 | — | — | CN | disclosed |
| CN-117529322-A | Compounds and methods for treating chemotherapy-related gastrointestinal side effects | 上海岸阔医药科技有限公司 | 2024-02-06 | — | — | CN | disclosed |
| CN-116731147-A | Method for preparing fucosylated and defucosylated forms of proteins | 豪夫迈·罗氏有限公司 | 2023-09-12 | — | — | CN | disclosed |
| US-11723983-B2 | Conjugates of a glycoprotein or a glycan with a toxic payload | GLYKOS FINLAND OY (FI) | 2023-08-15 | — | — | US | disclosed |
| WO-2004042064-A2 | DISORDERS OF LIPID METABOLISM | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2004-05-21 | — | — | WO | disclosed |
| EP-1362885-A1 | Antimicrobially treated material and methods of preventing coloring thereof | Nakamura, Kenji (JP) | 2003-11-19 | — | — | EP | disclosed |
| EP-0370205-B1 | Glycosylated polypeptides | KYOWA HAKKO KOGYO KK (JP) | 1998-07-22 | — | — | EP | disclosed |
| EP-0458901-B1 | INHIBITING TRANSFORMATION OF CELLS HAVING ELEVATED PURINE METABOLIC ENZYME ACTIVITY | MASSACHUSETTS INST TECHNOLOGY (US) | 1997-12-17 | — | — | EP | disclosed |
| EP-0758681-A2 | Inhibiting transformation of cells having elevated purine metabolic enzyme activity | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1997-02-19 | — | — | EP | disclosed |
| US-5218092-A | Stability | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1993-06-08 | — | — | US | disclosed |
| EP-0458901-A1 | INHIBITING TRANSFORMATION OF CELLS HAVING ELEVATED PURINE METABOLIC ENZYME ACTIVITY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1991-12-04 | — | — | EP | disclosed |
| WO-1990009192-A1 | INHIBITING TRANSFORMATION OF CELLS HAVING ELEVATED PURINE METABOLIC ENZYME ACTIVITY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1990-08-23 | — | — | WO | disclosed |
| EP-0370205-A2 | Glycosylated polypeptides | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1990-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11723983-B2 | Conjugates of a glycoprotein or a glycan with a toxic payload | FUT6, CD44, SIGLEC7 | CA4 1584/4885CA2 3909/4885SLC34A1 1794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.